

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 6 -->
<!-- Creation date: 2015-05-12T03:38:41Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ardx="http://www.ardelyx.com/20150331" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ardx-20150331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE780538--1510-Q0003_STD_0_20150228_0_1280964x1425334" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_7449706_EF526663-B23E-4EB0-BACE-2877147E0163_2001_1">12.43</us-gaap:SharesIssuedPricePerShare>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_0_20150508_0" unitRef="shares" decimals="INF" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_2_5">18651835</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE780538--1510-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1002_23">33221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_30">18635071</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_31">18635071</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_29">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_26">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_28">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_24">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_23">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_25">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_18">27190000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_14">470000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PreferredStockValue contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_22" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_16">19912000</us-gaap:LiabilitiesCurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="INF" id="id_7449706_D7907976-371B-4AF3-8E45-A3C8E6284BB4_1001_0">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_27">3000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_20" />
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_12">2544000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_33">-75369000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_32">133366000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_34">58000000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_17">297000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_35">105399000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="INF" id="id_7449706_D7907976-371B-4AF3-8E45-A3C8E6284BB4_1001_1">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_15">15953000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Liabilities contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_19">47399000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_13">945000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1001_23">98318000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_6">3289000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_4">1545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_8">100000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:Assets contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_9">105399000</us-gaap:Assets>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_3">2043000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_7">104000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_1_5">101906000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1269048_1275669x1270387_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_3003_3">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1269048_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_1003_4">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1272304_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_4002_2">97737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1272304_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_1002_4">97737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_7449706_BD72930D-7053-465C-A2B3-01ABCA4A4367_1001_0">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1270313x1965938" unitRef="iso4217_USD" decimals="-5" id="id_7449706_BD72930D-7053-465C-A2B3-01ABCA4A4367_1002_0">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:DeferredRevenue contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1272072x1385879" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_3001_2">43100000</us-gaap:DeferredRevenue>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275669x1270387_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_3001_3">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_4001_2">97737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_B02E5147-7CCD-4C56-8956-F5907D5E904E_1001_4">97837000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE780538--1510-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2001_22">34435000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_30">18589245</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_31">18589245</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_29">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_26">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_28">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_24">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_23">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_25">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_18">31074000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_14">780000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PreferredStockValue contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_22" />
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_16">21536000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_27">2000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_20" />
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_12">3129000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_33">-71867000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_32">132547000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_34">60682000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_17">122000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_35">113414000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_15">15979000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Liabilities contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_19">52732000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_13">1648000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_3001_22">107286000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_6">2131000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_4">1209000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_8">100000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:Assets contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_9">113414000</us-gaap:Assets>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_3">2584000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_7">104000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_24D0A804-5D6C-4237-AE50-1CC13E80EDDD_2_5">111079000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1269048_1275669x1270387_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_3003_3">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1269048_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_1003_4">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1272304_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_4002_2">105410000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1272304_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_1002_4">105410000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DeferredRevenue contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1272072x1385879" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_3003_2">47100000</us-gaap:DeferredRevenue>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275669x1270387_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_3001_3">100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_4001_2">105410000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_7449706_905E41AC-CAF0-492F-89F1-50973D41C27C_1001_4">105510000</us-gaap:AssetsFairValueDisclosure>
  <ardx:NumberOfPatients contextRef="eol_PE780538--1510-Q0003_STD_1_20150505_0_1271378x1273350" unitRef="Patient" decimals="INF" id="id_7449706_65B24012-A080-4B6C-8FAE-367BB4A89995_1001_0">154</ardx:NumberOfPatients>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE780538--1510-Q0003_STD_28_20150228_0_1280964x1425334" unitRef="shares" decimals="INF" id="id_7449706_EF526663-B23E-4EB0-BACE-2877147E0163_1001_0">19614</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE780538--1510-Q0003_STD_28_20150228_0_1280964x1425334" unitRef="iso4217_USD" decimals="-5" id="id_7449706_EF526663-B23E-4EB0-BACE-2877147E0163_1001_2">200000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="eol_PE780538--1510-Q0003_STD_31_20121031_0_1272072x1385879" unitRef="iso4217_USD" decimals="-5" id="id_7449706_9B67A9F3-E196-40E7-8182-5DDB8429B981_1001_0">35000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="eol_PE780538--1510-Q0003_STD_31_20140531_0_1272072x1385879" unitRef="iso4217_USD" decimals="-5" id="id_7449706_871FA981-6355-4B62-868A-D28CC73FA37B_1001_0">25000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE780538--1510-Q0003_STD_31_20140531_0_1272072x1515548" unitRef="iso4217_USD" decimals="-4" id="id_7449706_6DA33BBD-AF32-48CE-80B6-9FD20DD979DA_1001_0">1250000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="eol_PE780538--1510-Q0003_STD_365_20131231_0_1272072x1385879" unitRef="iso4217_USD" decimals="-5" id="id_7449706_9B67A9F3-E196-40E7-8182-5DDB8429B981_1002_0">15000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_15">-2.44</us-gaap:EarningsPerShareDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_14">-1120000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_7449706_61D76CCF-13F0-4B21-983E-38833DC145BB_2_3">1256245</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_17">1256245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_14">-2.44</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_61D76CCF-13F0-4B21-983E-38833DC145BB_2_4">-2.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="shares" decimals="-5" id="id_7449706_CFCC4A58-F252-4CD4-A8BF-1F3B78E25C0A_2_0">1100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_16">1256245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:LicensesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_1">3236000</us-gaap:LicensesRevenue>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_9">296000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_11">-3071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_8">-464000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_9">-4000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_3">8550000</us-gaap:Revenues>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_2">5314000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_16">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_1">-3071000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_8">-1459000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_2_2">64000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_13">-2434000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_11">-326000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_7">9014000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_5">7637000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_21">-1214000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_5">2603000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_12">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_3">73000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_12">562000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_17">-94000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_2_6">1377000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_10">246000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_2_4">64000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629" unitRef="shares" decimals="INF" id="id_7449706_6DAAFBCA-FD5D-4938-BE67-A2FE2C48C94B_1002_0">46797</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_1002_1">27000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_2002_0">37000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0_1272072x1385879_1280342x1630873" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_1002_0">3200000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20140331_0_1272072x1385879_1280342x1630874" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_2002_1">5300000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_CD7AED5A-EBC6-4823-8404-B883A6BC2289_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 4. COLLABORATION AND LICENSING AGREEMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;AstraZeneca AB (&amp;#x201C;AstraZeneca&amp;#x201D;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2012, the Company entered into a collaboration
 partnership with AstraZeneca for the worldwide development and
 commercialization of tenapanor. Under the terms of the AstraZeneca
 collaboration partnership agreement (the &amp;#x201C;AstraZeneca
 Agreement&amp;#x201D;), the Company received an up-front license fee of
 $35.0 million in October 2012 and a $15.0 million payment in
 December 2013, which are both being recognized as revenue on a
 straight-line basis over the estimated period of performance. The
 estimated period of performance during the three months ended
 March&amp;#xA0;31, 2015 was estimated to be December 2017, which
 represented the estimated completion date of the Phase 2b clinical
 trials in chronic kidney disease, or CKD, to be conducted with
 tenapanor. The expected period of performance is reviewed quarterly
 and adjusted, as needed, to reflect our current assumptions
 regarding the timing of clinical studies. AstraZeneca reimburses
 the Company for its internal and external development-related
 costs. These reimbursements are recognized as collaborative
 development revenue when the development-related costs are
 incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Company received from AstraZeneca a $25.0 million
 payment as a result of the dosing of the first patient in the Phase
 2b clinical trial in hyperphosphatemia. As the $25.0 million did
 not meet the criteria to be considered the achievement of a
 substantive milestone for accounting purposes, the amount was
 recorded as deferred revenue when received and is being recognized
 as revenue on a straight-line basis over the remaining estimated
 period of performance under the AstraZeneca Agreement, which during
 the three months ended March&amp;#xA0;31, 2015 was estimated to be
 December 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the three months ended March&amp;#xA0;31, 2015 and 2014, the
 Company recognized revenue of $3.9 million and $3.2 million,
 respectively, related to amortization of the up-front and other
 license fees, and $2.0 million and $5.3 million, respectively, for
 collaborative development services. As of March&amp;#xA0;31, 2015 and
 December&amp;#xA0;31, 2014, the Company had total deferred revenue of
 $43.1 million and $47.1 million related to the AstraZeneca
 Agreement, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Sanofi SA (&amp;#x201C;Sanofi&amp;#x201D;)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2014, the Company entered into a license option and
 license agreement with Sanofi (the &amp;#x201C;Sanofi Agreement&amp;#x201D;)
 for its phosphate transport NaP2b inhibitor program. Under the
 terms of the Sanofi Agreement, the Company granted Sanofi an
 exclusive worldwide license to conduct research utilizing the
 Company&amp;#x2019;s small molecule NaP2b inhibitors. In addition,
 Sanofi has the option to obtain an exclusive license to develop,
 manufacture and commercialize potential products under the
 agreement. Under the License Option and License Agreement, Sanofi
 is responsible for all of the costs and expenses for research and
 preclinical activities and, should it exercise its option, for the
 development and commercialization efforts under the program.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Under the Sanofi Agreement, the Company received a payment of $1.25
 million in March 2014, which was fully recognized as licensing
 revenue in May 2014 after the Company completed its obligation to
 provide to Sanofi the background know-how, listed patents, and
 materials described in the Sanofi Agreement.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_15">-0.19</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_F1899E3F-9185-4A60-955F-0C33B7E8C72A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 6. NET LOSS PER COMMON SHARE&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per common share is calculated by dividing the net
 loss by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per common share is
 computed giving effect to all potential dilutive common shares,
 including common stock issuable upon exercise of stock options, and
 unvested restricted common stock and stock units. As the Company
 had net losses for the three months ended March&amp;#xA0;31, 2015 and
 2014, all potential common shares were determined to be
 anti-dilutive. Basic and diluted earnings per common share are
 calculated as follows (in thousands, except share and per share
 data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Weighted average number of shares outstanding - basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,606,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,256,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share - basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.19&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For the three months ended March&amp;#xA0;31, 2015 and 2014, the total
 number of anti-dilutive outstanding common stock options excluded
 from the net income per common share computation was
 1.2&amp;#xA0;million and 1.1&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <dei:DocumentType contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C94B4071-A4F7-41E4-962D-E696745C89D1_1_0">10-Q</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_1_1">Ardelyx, Inc.</dei:EntityRegistrantName>
  <dei:TradingSymbol contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_1_0">ARDX</dei:TradingSymbol>
  <dei:EntityFilerCategory contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_14">-8209000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C341B3CC-5320-423C-AC0C-E87968ECA02E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Ardelyx, Inc. (the &amp;#x201C;Company&amp;#x201D;) is a clinical stage
 biopharmaceutical company focused on the discovery, development and
 commercialization of innovative, minimally-systemic, small molecule
 therapeutics that work exclusively in the gastrointestinal tract to
 treat cardio-renal, gastrointestinal and metabolic diseases. The
 Company has developed a drug discovery and design platform enabling
 it, in a rapid and cost-efficient manner, to discover and design
 novel drug candidates. Utilizing its platform, the Company
 discovered and designed our lead product candidate, tenapanor,
 which in clinical studies has demonstrated the ability to improve
 the symptoms of constipation-predominant irritable bowel syndrome,
 or IBS-C, and to reduce the absorption of dietary sodium as well as
 phosphorus, a key component in the management of hyperphosphatemia
 in dialysis patients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 These unaudited condensed financial statements and the related
 footnote information of the Company have been prepared pursuant to
 the requirements of the Securities and Exchange Commission (the
 &amp;#x201C;SEC&amp;#x201D;) for interim reporting. As permitted under those
 rules and regulations, certain footnotes or other financial
 information that are normally required by U.S. generally accepted
 accounting principles have been condensed or omitted pursuant to
 such rules and regulations. In the opinion of the Company&amp;#x2019;s
 management, the accompanying interim unaudited condensed financial
 statements include all adjustments (consisting only of normal
 recurring adjustments) necessary for a fair presentation of the
 information for the periods presented. The results for the quarter
 ended March&amp;#xA0;31, 2015 are not necessarily indicative of results
 to be expected for the entire year ending December&amp;#xA0;31, 2015 or
 future operating periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accompanying condensed financial statements and related
 financial information should be read in conjunction with the
 audited financial statements and the related notes thereto for the
 year ended December&amp;#xA0;31, 2014, included in the Company&amp;#x2019;s
 Annual Report on Form 10-K filed with the SEC (the 2014 Form 10-K).
 The balance sheet at December&amp;#xA0;31, 2014 has been derived from
 the audited financial statements at that date, as filed with the
 2014 Form 10-K.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_BE45C5AE-5430-4814-8E8D-BE334AACC249_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table presents stock-based compensation expense
 recognized for stock options and the Company&amp;#x2019;s employee stock
 purchase program (the &amp;#x201C;ESPP&amp;#x201D;) in the Company&amp;#x2019;s
 statements of operations (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &amp;#xA0;&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_56F61E36-D366-4730-8172-42F621F0E568_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Revenue from research activities made under collaboration
 partnership agreements are recognized as the services are provided
 and when there is persuasive evidence that an arrangement exists,
 delivery has occurred, the price is fixed or determinable, and
 collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes up-front
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments, and royalties on
 future licensees&amp;#x2019; product sales.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 For revenue agreements with multiple-element arrangements, such as
 license and development agreements, the Company allocates revenue
 to each deliverable based on the relative selling price of each
 deliverable. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 vendor-specific objective evidence or third-party evidence. If
 neither exists, the Company uses its best estimate of selling price
 for that deliverable. Revenue allocated is then recognized when the
 four basic revenue recognition criteria are met for each
 deliverable.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company recognizes revenue from upfront payments ratably over
 the term of its estimated period of performance under the agreement
 which is recorded as licensing revenue. Reimbursements for
 development costs incurred under the Company&amp;#x2019;s license
 agreement with AstraZeneca are classified as collaborative
 development revenue. The Company recognizes cost reimbursement
 revenue under collaboration partnership agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which has not been earned.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Revenues from milestones, if they are nonrefundable and deemed
 substantive, are recognized upon successful accomplishment of the
 milestones. To the extent that non-substantive milestones are
 achieved and the Company has remaining performance obligations,
 milestones are deferred and recognized as revenue over the
 estimated remaining period of performance. The Company will
 recognize revenue associated with the non-substantive milestones
 upon achievement of the milestone if there are no undelivered
 elements and it has no remaining performance obligations. The
 Company will account for sales-based milestones as royalties that
 will be recognized as revenue upon achievement of the
 milestone.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_2D131A2D-3C74-4746-AB88-D9ADE02E3635_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The preparation of financial statements in conformity with U.S.
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Although
 management believes these estimates are based upon reasonable
 assumptions within the bounds of its knowledge of the
 Company&amp;#x2019;s business and operations, actual results could
 differ materially from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="shares" decimals="0" id="id_7449706_61D76CCF-13F0-4B21-983E-38833DC145BB_1_3">18606760</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C94B4071-A4F7-41E4-962D-E696745C89D1_1_2">2015-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_57A42EDF-D83C-4753-94F2-005C410844DD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 7. STOCKHOLDERS EQUITY&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Option Exercises&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the three months ended March&amp;#xA0;31, 2015 employees exercised
 options to purchase 26,212 shares of the Company&amp;#x2019;s common
 stock with net proceeds to the Company of approximately $0.1
 million. For the three months ended March&amp;#xA0;31, 2014, employees
 exercised options to purchase 46,797 shares of the Company&amp;#x2019;s
 common stock with insignificant net proceeds to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2015, the Company sold 19,614 shares under the ESPP.
 The shares were purchased at a purchase price of $12.43 per share
 with proceeds to the Company of approximately $0.2 million.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C94B4071-A4F7-41E4-962D-E696745C89D1_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C94B4071-A4F7-41E4-962D-E696745C89D1_1_3">2015</dei:DocumentFiscalYearFocus>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="shares" decimals="0" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_17">18606760</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_14">-0.19</us-gaap:EarningsPerShareBasic>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_CEB1C022-719C-4600-99EE-81A88639E9F1_1_0">&lt;div&gt;
 &lt;p&gt;Basic and diluted earnings per common share are calculated as
 follows (in thousands, except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,502&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Weighted average number of shares outstanding - basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,606,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,256,245&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share - basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.19&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_526A9BC1-49AC-42DB-BF04-AA98FC953A2B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with U.S.
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and accompanying notes. Although
 management believes these estimates are based upon reasonable
 assumptions within the bounds of its knowledge of the
 Company&amp;#x2019;s business and operations, actual results could
 differ materially from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Revenue from research activities made under collaboration
 partnership agreements are recognized as the services are provided
 and when there is persuasive evidence that an arrangement exists,
 delivery has occurred, the price is fixed or determinable, and
 collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes up-front
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments, and royalties on
 future licensees&amp;#x2019; product sales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For revenue agreements with multiple-element arrangements, such as
 license and development agreements, the Company allocates revenue
 to each deliverable based on the relative selling price of each
 deliverable. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 vendor-specific objective evidence or third-party evidence. If
 neither exists, the Company uses its best estimate of selling price
 for that deliverable. Revenue allocated is then recognized when the
 four basic revenue recognition criteria are met for each
 deliverable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes revenue from upfront payments ratably over
 the term of its estimated period of performance under the agreement
 which is recorded as licensing revenue. Reimbursements for
 development costs incurred under the Company&amp;#x2019;s license
 agreement with AstraZeneca are classified as collaborative
 development revenue. The Company recognizes cost reimbursement
 revenue under collaboration partnership agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which has not been earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Revenues from milestones, if they are nonrefundable and deemed
 substantive, are recognized upon successful accomplishment of the
 milestones. To the extent that non-substantive milestones are
 achieved and the Company has remaining performance obligations,
 milestones are deferred and recognized as revenue over the
 estimated remaining period of performance. The Company will
 recognize revenue associated with the non-substantive milestones
 upon achievement of the milestone if there are no undelivered
 elements and it has no remaining performance obligations. The
 Company will account for sales-based milestones as royalties that
 will be recognized as revenue upon achievement of the
 milestone.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Financial Accounting Standards Board (the
 &amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update 2014-09,
 &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&amp;#x201C;ASU
 2014-09&amp;#x201D;), which converges the FASB and the International
 Accounting Standards Board standards on revenue recognition. Areas
 of revenue recognition that will be affected include, but are not
 limited to, transfer of control, variable consideration, allocation
 of transfer pricing, licenses, time value of money, contract costs
 and disclosures. This guidance is effective for the fiscal years
 and interim reporting periods beginning after December&amp;#xA0;15,
 2016, at which time the Company may adopt the new standard under
 the full retrospective method or the modified retrospective method.
 Early adoption is not permitted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On April&amp;#xA0;1, 2015, the FASB voted to propose a delay in the
 effective date of ASU No.&amp;#xA0;2014-09. The proposed new effective
 date will be annual reporting periods beginning after
 December&amp;#xA0;15, 2017, and the interim periods within that year
 and will allow early adoption for all entities as of the original
 effective date for public business entities, which was annual
 reporting periods beginning after December&amp;#xA0;15, 2016. The
 Company has not yet selected a transition method nor has the
 Company determined the impact of the new standard on its condensed
 financial statements and related disclosures.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_D2F4DEDA-4575-4448-B4C6-71B9208D4585_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;NOTE 8. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On May&amp;#xA0;5, 2015, the Company announced that a 154-patient Phase
 2a clinical trial evaluating tenapanor in Stage 3 chronic kidney
 disease patients with type 2 diabetes mellitus and albuminuria did
 not meet the primary endpoint of decreasing the urinary
 albumin-creatinine ratio in tenapanor-treated patients compared to
 patients receiving placebo. With the completion of this Phase 2a
 clinical trial, the Company and AstraZeneca are assessing the data
 from all the trials.&amp;#xA0;Under the terms of the AstraZeneca
 Agreement, AstraZeneca is obligated to communicate to the Company,
 on or before June&amp;#xA0;29, 2015, whether it will continue the
 development of tenapanor.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_4EF5FC0D-8778-42EC-B2BC-3918CF31E5C8_1_2">0001437402</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_940D2979-3E93-417A-BBFC-12A45C68359E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;NOTE 5. STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table presents stock-based compensation expense
 recognized for stock options and the Company&amp;#x2019;s employee stock
 purchase program (the &amp;#x201C;ESPP&amp;#x201D;) in the Company&amp;#x2019;s
 statements of operations (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 At March&amp;#xA0;31, 2015, the Company had $5.9 million and $0.2
 million of total unrecognized compensation expense, net of
 estimated forfeitures, related to stock option grants and purchase
 rights, respectively, that will be recognized over an average
 vesting period of 2.9 years and 0.4 years, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_7449706_61D76CCF-13F0-4B21-983E-38833DC145BB_1_4">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_CCBB14A1-9380-4BE1-9D9F-97BE814F887E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following table sets forth the fair value of the
 Company&amp;#x2019;s financial assets measured on a recurring basis by
 level within the fair value hierarchy (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;March&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,837&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_BA74B662-86BA-4A6D-AC19-03E031DF6590_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;NOTE 3. FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants on the
 measurement date. Valuation techniques used to measure fair value
 must maximize the use of observable inputs and minimize the use of
 unobservable inputs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The three-level hierarchy for the inputs to valuation techniques is
 briefly summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations are based on quoted prices in active
 markets for identical assets or liabilities and readily accessible
 by us at the reporting date. Examples of assets and liabilities
 utilizing Level 1 inputs are certain money market funds, U.S.
 Treasuries and trading securities with quoted prices on active
 markets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;Level 2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations based on inputs other than the quoted
 prices in active markets that are observable either directly or
 indirectly in active markets. Examples of assets and liabilities
 utilizing Level 2 inputs are U.S. government agency bonds,
 corporate bonds, commercial paper, certificates of deposit and
 over-the-counter derivatives.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations based on unobservable inputs in which
 there is little or no market data, which require us to develop our
 own assumptions.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The following table sets forth the fair value of the
 Company&amp;#x2019;s financial assets measured on a recurring basis by
 level within the fair value hierarchy (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;March&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,837&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr style="COLOR: white; LINE-HEIGHT: 0pt; VISIBILITY: hidden"&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Where quoted prices are available in an active market, securities
 are classified as Level 1. The Company classifies money market
 funds as Level 1. When quoted market prices are not available for
 the specific security, then the Company estimates fair value by
 using benchmark yields, reported trades, broker/dealer quotes, and
 issuer spreads. The Company classifies certificates of deposit as
 Level&amp;#xA0;2. In certain cases where there is limited activity or
 less transparency around inputs to valuation, securities are
 classified as Level&amp;#xA0;3. There were no transfers between Level 1
 and Level 2 during the periods presented.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_557D2D50-D2D3-4679-89C4-DAB3610BDAB8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the Financial Accounting Standards Board (the
 &amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update 2014-09,
 &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&amp;#x201C;ASU
 2014-09&amp;#x201D;), which converges the FASB and the International
 Accounting Standards Board standards on revenue recognition. Areas
 of revenue recognition that will be affected include, but are not
 limited to, transfer of control, variable consideration, allocation
 of transfer pricing, licenses, time value of money, contract costs
 and disclosures. This guidance is effective for the fiscal years
 and interim reporting periods beginning after December&amp;#xA0;15,
 2016, at which time the Company may adopt the new standard under
 the full retrospective method or the modified retrospective method.
 Early adoption is not permitted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On April&amp;#xA0;1, 2015, the FASB voted to propose a delay in the
 effective date of ASU No.&amp;#xA0;2014-09. The proposed new effective
 date will be annual reporting periods beginning after
 December&amp;#xA0;15, 2017, and the interim periods within that year
 and will allow early adoption for all entities as of the original
 effective date for public business entities, which was annual
 reporting periods beginning after December&amp;#xA0;15, 2016. The
 Company has not yet selected a transition method nor has the
 Company determined the impact of the new standard on its condensed
 financial statements and related disclosures.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_C94B4071-A4F7-41E4-962D-E696745C89D1_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="shares" decimals="-5" id="id_7449706_CFCC4A58-F252-4CD4-A8BF-1F3B78E25C0A_1_0">1200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" id="id_7449706_E6DC6679-0BB2-45E1-B3F3-3DCBEF445C45_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants on the
 measurement date. Valuation techniques used to measure fair value
 must maximize the use of observable inputs and minimize the use of
 unobservable inputs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The three-level hierarchy for the inputs to valuation techniques is
 briefly summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;Level&amp;#xA0;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations are based on quoted prices in active
 markets for identical assets or liabilities and readily accessible
 by us at the reporting date. Examples of assets and liabilities
 utilizing Level 1 inputs are certain money market funds, U.S.
 Treasuries and trading securities with quoted prices on active
 markets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;Level 2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations based on inputs other than the quoted
 prices in active markets that are observable either directly or
 indirectly in active markets. Examples of assets and liabilities
 utilizing Level 2 inputs are U.S. government agency bonds,
 corporate bonds, commercial paper, certificates of deposit and
 over-the-counter derivatives.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;Level&amp;#xA0;3&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2013;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Valuations based on unobservable inputs in which
 there is little or no market data, which require us to develop our
 own assumptions.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="shares" decimals="0" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_16">18606760</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_25">236000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:LicensesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_1">3884000</us-gaap:LicensesRevenue>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_9">336000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_11">-3502000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_6">-11000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_8">-3490000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_9">-12000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_3">5883000</us-gaap:Revenues>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_2">1999000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_16">1055000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_1">-3502000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_8">-541000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_1_2">524000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_13">-3910000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_11">-703000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_7">9373000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_5">6198000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_21">-8968000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_12">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_3">119000</us-gaap:DepreciationAndAmortization>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_20">296000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_12">-134000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_17">-1055000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_19">296000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:FairValueOfAssetsAcquired contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_27">234000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_25D74070-C7B3-4F82-82B7-FB7E0A3F4C5D_1_6">3175000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_10">-819000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_7449706_45E7DC68-EBA3-4469-8CD9-1B62E2B5E7F7_1_4">524000</us-gaap:ShareBasedCompensation>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629" id="id_7449706_BD72930D-7053-465C-A2B3-01ABCA4A4367_1_1">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629" unitRef="shares" decimals="INF" id="id_7449706_6DAAFBCA-FD5D-4938-BE67-A2FE2C48C94B_1001_0">26212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_7449706_6DAAFBCA-FD5D-4938-BE67-A2FE2C48C94B_1001_1">100000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_1001_1">238000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_7449706_C3796304-1825-4C89-A7C1-66E03E47541D_2001_0">286000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1965938" id="id_7449706_BD72930D-7053-465C-A2B3-01ABCA4A4367_2_1">P4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1272072x1385879_1280342x1630873" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_1001_0">3900000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE780538--1510-Q0003_STD_90_20150331_0_1272072x1385879_1280342x1630874" unitRef="iso4217_USD" decimals="-5" id="id_7449706_3DD9BEE7-9704-404A-9987-18FB82733179_2001_1">2000000</us-gaap:LicenseAndServicesRevenue>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1272072x1385879_1280342x1630874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ardx:CollaborativeDevelopmentServicesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1272072x1385879_1280342x1630873">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ardx:AmortizationOfUpFrontAndOtherLicenseFeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1965938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PurchaseRightsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0_1272072x1385879_1280342x1630874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ardx:CollaborativeDevelopmentServicesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0_1272072x1385879_1280342x1630873">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ardx:AmortizationOfUpFrontAndOtherLicenseFeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_365_20131231_0_1272072x1385879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_31_20140531_0_1272072x1515548">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:SanofiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_31_20140531_0_1272072x1385879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_31_20121031_0_1272072x1385879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_28_20150228_0_1280964x1425334">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-02-01</startDate>
      <endDate>2015-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_1_20150505_0_1271378x1273350">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-05-05</startDate>
      <endDate>2015-05-05</endDate>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275669x1277587_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1275669x1270387_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1272072x1385879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1272304_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1272304_1275669x1277587_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1269048_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0_1269038x1269048_1275669x1270387_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275669x1277587_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1275669x1270387_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1272072x1385879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ardx:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1270313x1965938">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PurchaseRightsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1270313x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1272304_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1272304_1275669x1277587_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1269048_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0_1269038x1269048_1275669x1270387_1275672x1274022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150508_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
    </entity>
    <period>
      <instant>2015-05-08</instant>
    </period>
  </context>
  <context id="eol_PE780538--1510-Q0003_STD_0_20150228_0_1280964x1425334">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-02-28</instant>
    </period>
  </context>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Patient">
    <measure>ardx:Patient</measure>
  </unit>
</xbrl>